News for Health Professionals Archive - August 2012
Get news by email or subscribe to our news feeds.
August 1, 2012
- Hospira Reports Second-Quarter 2012 Results
- Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Amylin Pharmaceuticals, Inc.
- Welichem and Stiefel, a GSK company, complete the acquisition by Stiefel of the novel anti-inflammatory agent, WBI-1001
- Pfizer Study: Arthritis Pill Beats Standard Drug
- European Medicines Agency Sees Benefits of Interaction With Japanese Regulators
- Cell Therapeutics, Inc. (CTI) Readies Pixuvri European Launch and Start of Pacritinib Phase 3 Trial; Reports Second Quarter Financial Results and Milestones
- Shire Second Quarter Product Sales Up 16%
- AmeriSourceBergen Wins $18.5 Billion Express Scripts Contract
- Shire Shares Climb After 2Q Profit Report
August 2, 2012
- Teva Reports Second Quarter 2012 Results
- Pharming Announces Restructuring Plan
- Gilead Sciences Announces New Collaboration with Indian Partners to Reduce Manufacturing Cost and Improve Availability of Emtricitabine-Based Antiretroviral Therapy in Developing Countries
- Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C
- Drug Combo Better for Common Type of Metastatic Breast Cancer, UCI-Led Study Finds
- Carl Icahn Issues Open Letter To Shareholders Of Forest Laboratories
- PhRMA Statement on Prescription Drug Costs
- Markey, House Dems Introduce Bill to Protect Human Subjects in Clinical Trials
- SEC Charges Bristol-Myers Squibb Executive With Insider Trading in Stock Options of Potential Acquisition Targets
August 3, 2012
- New Study Finds Generic Drugs Saved Consumers Over $1 Trillion
- Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity
- BMS Exec Charged in Insider Trading
- Incyte Stumbles Despite Posting 2Q Profit
- Valeant Posts 2Q Loss but Revenue Grows 35 Percent
August 6, 2012
- Johnson & Johnson Reaches Risperdal Lawsuit Agreement
- Tekmira Provides Update on Collaboration With U.S. Government's TMT Program
- Novartis and University of Pennsylvania Form Broad-Based R&D Alliance to Advance Novel T-Cell Immunotherapies to Treat Cancer
- Astellas to Close Urogenix, North Carolina-based Urology Research Facility
- K-V Pharmaceutical Company Files Voluntary Petitions for Reorganization to Restructure Financial Obligations
- Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
- SEC Opens Teva Bribery Probe
- Penn and Novartis Will Team on Cancer Research
- Court Grants Jury Trial For Failure To Warn Suit Against Drug Company
- Pluristem Therapeutics Climbs
- Life of Cancer Patient Suffering from Bone Marrow Failure Saved Following Treatment with Pluristem's PLX Cells
August 7, 2012
- Pfizer Announces Co-Primary Clinical Endpoints Not Met In Second Phase 3 Bapineuzumab Study In Mild-To-Moderate Alzheimer's Disease Patients Who Do Not Carry The Apoe4 Genotype
- Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimer's Disease
- Tensions Rise Between Teva CEO and CFO
- Isis Pharmaceuticals Rises on Strong 2Q Results
- Drug Companies Are Teaming With Academic Medical Centers to Create New Medicines, According to Tufts Center for the Study of Drug Development
- Mannkind 2Q Loss Narrows on Year-Ago Payment
- Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations
August 8, 2012
- Pfizer Will Market Epipen Syringe in Japan
- Pfizer Gaucher Payment Pushes Protalix Into Profit
- Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis
- Lundbeck on Track to Meet Financial Expectations and Renew Its Product Portfolio to Secure Long-Term Growth
- Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
August 9, 2012
- Novo Nordisk Increased Operating Profit by 31% in the First Half of 2012
- Ranbaxy Returns Sales Growth of 55% in Q2 2012 with Stronger Profitablity; Receives Approval for Multiple Value Added, Differentitated Products
- Hospira Announces U.S. Re-Launch Of Generic Oxaliplatin Injection
- Takeda and Millennium Termination of Ganitumab Phase III Study in Metastatic Pancreatic Cancer in Japan
- Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
- Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin
- Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals, Inc.
August 10, 2012
- PhRMA Statement on Flawed British Medical Journal Analysis
- K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court
- Mylan Receives FDA OK for Lithium Carbonate Dose
- PharmAthene Receives FDA Notification On SparVax
- FDA Ends Orphan Exclusivity for Octapharma Drug Wilate
- Amgen Shutting Down Epogen Manufacturing
August 13, 2012
- Zoetis Files IPO Registration Statement
- Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders
- Sun Pharma to Take Taro Private
- Stop Drug Trials in China: Lawyer
- Forest Laboratories Issues Open Letter to Shareholders
- InSite Vision & Merck Amend Payment Terms of AzaSite License Agreement
- Icahn Responds To Forest Labs Board
- Pfizer And Astrazeneca Enter Into Agreement For Over-The-Counter Nexium
- FDA Approves Vaccines for the 2012-2013 Influenza Season
August 14, 2012
- Shire CEO Says Company Nearing Decision on Move
- Octagon Research Solutions Acquired By Accenture PLC
- FDA Approves Vaccines for the 2012-2013 Influenza Season
- Share of Physicians Seeing iPad Reps Doubles between 2011 and 2012 - 65 Percent of ePharma Physicians Who See Reps Have Seen an iPad Rep
- Cortex Pharmaceuticals and Pier Pharmaceuticals Consummate Merger
- Boehringer Ingelheim Achieves Further Growth in First Half of 2012 ? Difficult Business Environment Expected for the Second Half of the Year
- Upsher-Smith Completes Acquisition of Proximagen Group plc
- Q2 2012: Merck Transformation Starts to Yield First Results
- AstraZeneca and Pfizer Enter Agreement for Over-the-Counter Nexium; AstraZeneca Raises 2012 Guidance
- Icahn Comments On Warning Letter Just Sent By FDA To Forest
- IMS Health Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd.
- Target Survey Shows Adult Americans May Avoid the Flu Shot Due to Fear of Needles
August 15, 2012
- Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
- USF Files Suit Over Research Patent Deal
- Bristol-Myers Squibb Announces Specialty Pharmacy Patient Management Programs For Sprycel® (dasatinib) Patients
- GlaxoSmithKline Reaches Agreement to Divest Majority of Classic Brands in Australia for £172m
- Array Biopharma Posts Smaller Fiscal 4Q Loss
- Watson Sues FDA Regarding Delay of Generic Actos Approval
- Carl Icahn Wins Seat On Forest Labs Board
- IMS Health Acquires TTC, Strengthening Pharma R&D Services Capabilities
- FDA Warns of Risk of Death from Codeine Use in Some Children Following Surgeries
- Latest Top 100 Drug Sales Data Released: Loss of Patent Protection Has Significant Effect
August 16, 2012
August 17, 2012
- Pluristem Obtains Indian Phase II Trial Approval
- Biotech Firm Has Plans to Grow in Tucson
- Morphotek Set to Begin Production Near Philly
August 20, 2012
- Dainippon Sumitomo Pharma Announces Organizational Changes: Establishment of the ?DSP Cancer Institute?
- Dyax Corp. Creates COO Position and Expands Executive Roles
- Reckitt Benckiser Pharmaceuticals Inc. Announces FDA Approval of Two New Dosage Strengths of Suboxone Sublingual Film (C-III) for Maintenance Treatment of Opioid Dependence
- India's CRO Market Poised to Grow
August 21, 2012
- Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
- Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
- Article Preview211 People Died in Six Months During Clinical Trials in India
- Indian Court to Hear Crucial Novartis Patent Case on Cut-Price Generic Drugs
- FDA Issues New Safety Alert on Reumofan Plus and Reumofan Plus Premium
August 22, 2012
- EpiCept Announces Resignation of CEO Jack Talley
- Abbott Cholesterol Drug Subject of False-Marketing Suit
- SEC Charges Former Array BioPharma Manager For Insider Trading
- SEC Fines Ex-Array Biopharma Manager $150K As Part of Insider-Trading Probe
- G2: the Big Sleep: One in 10 Britons Now Use Sleeping Pills Regularly, Costing the NHS Pounds 50m A Year.
- Mike Golic, ESPN Radio Personality and Former Philadelphia Eagle, Holds Pre-Season "Training Camp" for People With Type 2 Diabetes
- Existing Anti-Fungal Drug May Treat Cancer
- Merck KGaA Acquires Cell Culture Media Specialist Biochrom AG
August 23, 2012
- Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
- Gilead Terminates Cicletanine Trial; All Eyes Remain on Quad
- Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
- NICE: Breast Cancer Treatment Does Not Provide Enough Benefit for Patients to Justify its Cost
August 24, 2012
- Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C
- Statement on FDA Decision Regarding Endo Citizen Petition and Approval of a Generic Formulation of Lidoderm
- GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD
- Synergy Pharmaceuticals Acquires FV-100 Shingles Drug From Bristol-Myers Squibb Company
- Agennix AG Announces Corporate Restructuring
- Hospira to Create 200 Jobs in N.C.
- Pluristem Begins Phase II Artery-Disease Clinical Trial
August 27, 2012
- Merck Provides Update on Cardiovascular Development Programs
- Idenix Provides Update on IDX19368 Development Program
- Pfizer Gets Consents From Debt Holders
- Teva Loses Lung Cancer Drug Patent Appeal
August 28, 2012
- Pascal Soriot Appointed Chief Executive Officer of AstraZeneca
- Depomed Licenses Acuform Patents to J&J Division
August 29, 2012
- Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
- Small Pharma Co. Solving Big Problems
- Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
- SEC Charges Eight in Georgia-Based Insider Trading Ring
- FDA Approves tbo-filgrastim for Severe Neutropenia in Certain Cancer Patients
August 30, 2012
- FDA OKs Afinitor Disperz for Child Brain Tumors
- Kyowa Hakko Kirin Announces Temporary Suspension of Patient Enrollment for Phase 3 Clinical Study of ARQ 197 (Tivantinib) in Combination with Erlotinib in Non-Small-Cell Lung Cancer Patients
- FDA OKs Afinitor Disperz for Child Brain Tumors
- Sunovion Pharmaceuticals Inc. to Acquire Elevation Pharmaceuticals, Inc.
August 31, 2012
- Monthly News Round Up - August 2012
- VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
- FDA Approves Ironwood, Forest Labs Bowel Drug
- Revatio (sildenafil): Drug Safety Communication - Recommendation Against Use in Children
- Geron Jumps on Analyst View of Cancer Drugs
- Bristol-Myers Squibb Initiates Voluntary Recall of 10 Lots of BiCNU (carmustine for injection) Due to the Potential for Overfill
- Johnson & Johnson Settles Risperdal Case for $181 Million
